Co-sponsored Symposium

Co-sponsored Symposium 1
To Achieve Personal Goals for Patients with Schizophrenia in Patient Centered Care

2024年5月23日(木) 15:45 〜 17:45 Room 1 (Hall C)

Chair: Koichiro Watanabe (Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan), Nakao Iwata (Department of Psychiatry, Fujita Health University School of Medicine, Aichi, Japan)

Co-sponsored by Otsuka Pharmaceutical Co., Ltd.

+全てマイスケジュールに登録

[CSS1-1] The Significance of Personal Goals in Schizophrenia Treatment: Unmet Needs, Therapeutic Approaches, and Recovery Strategies

*Christoph U Correll^1,2 (1. Psychiatry and Molecular Medicine Zucker School of Medicine at Hofstra/Northwell, New York, USA, 2. Department of Child and Adolescent Psychiatry Charité University Medicine, Berlin, Germany)

[CSS1-2] Optimizing Antipsychotic Treatment for Relapse Prevention and Clinical Recovery in Schizophrenia

*Hiroyoshi Takeuchi¹ (1. Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan)

[CSS1-3] Psychosocial Treatment with a Focus on Recovery

*Naoki Hashimoto¹ (1. Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan)

Co-sponsored Symposium

Co-sponsored Symposium 2
Strategic Approaches to Achieve Recovery

2024年5月24日(金) 10:45 〜 12:00 Room 12 (Hall D5)

Chair: Hiroyuki Uchida (Department of Neuropsychiatry, Keio University School of Medicine)

Co-sponsored by Takeda Pharmaceutical Company Limited, Japan Medical Office/Lundbeck Japan K.K., Medical Affairs

+全てマイスケジュールに登録

[CSS2-1] MBCによるうつ病診療～症候学的寛解から機能的回復まで～

*高江洲義和¹ (1. 琉球大学大学院医学研究科精神病態医学講座)

[CSS2-2] うつ病患者のパーソナルリカバリー達成を目指す上で、いかに治療し、いかに測定するか

*坪井貴嗣¹ (1. 杏林大学医学部精神神経科学教室)

Co-sponsored Symposium

Co-sponsored Symposium 3
Cognitive Impairment is a Core Feature of Schizophrenia

2024年5月24日(金) 15:00 〜 16:00 Room 2 (Hall B7 (1))

Chair: Philip Harvey (Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine), Kazuyuki Nakagome (National Center of Neurology and Psychiatry)

Co-sponsored by Boehringer Ingelheim International GmbH

[CSS3] Cognitive Impairment Is a Core Feature of Schizophrenia

*Boehringer Ingelheim International GmbH

Co-sponsored Symposium

Co-sponsored Symposium 4
Tobacco Harm Reduction - an Update

2024年5月24日(金) 17:00 〜 19:00 Room 16 (G502)

Chair: Raymond S Niaura (New York University), Koji Takada (Department of Psyshiatry, Jikei University School of Medicine/Department of Psychology, Teikyo University)
Discussant: Naoyuki Hironaka (Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science)

Co-sponsored by Progressive Policy Institute

+全てマイスケジュールに登録

[CSS4-1] Harm reduction – origins, successes and untapped potential

*Katarzyna Kinga Kowalczyk¹ (1. Global Public Health Network)

[CSS4-2] Smoking, safer nicotine products and tobacco harm reduction―around the world in fifteen minutes

*David MacKintosh¹ (1. Knowledge•Action•Change)

[CSS4-3] Japan tops the world in reducing cigarette sales

*David Sweanor^1,2,3 (1. Centre for Health Law, Policy & Ethics, University of Ottawa、2. Faculty of Law, University of Ottawa、3. Global Leadership Council, Boston University School of Public Health)

[CSS4-4] Can e-cigarettes help tobacco cigarette smokers quit? A review of the evidence

*Raymond Niaura¹ (1. Departments of Social and Behavioral Sciences, Epidemiology/Department of Epidemiology, School of Global Public Health New York University)

[CSS4-5] Decision-making and habit: understanding maladaptive behaviour from basic animal learning research

*Yutaka Kosaki¹ (1. Department of Psychology, Waseda University)

Co-sponsored Symposium

Co-sponsored Symposium 5
Which interventions are key to change the trajectory of schizophrenia?

2024年5月25日(土) 14:30 〜 15:30 Room 1 (Hall C)

Chair: Hiroyuki Uchida (Department of Neuropsychiatry, Keio University School of Medicine)

Co-sponsored by Sumitomo Pharma Co.,Ltd. Medical Science

[CSS5] The relevance of nonpsychotic symptoms in the management of schizophrenia

*W. Wolfgang Fleischhacker¹ (1. Medical University Innsbruck)

Co-sponsored Symposium

Co-sponsored Symposium 6
Measurement Based Care in depression

2024年5月25日(土) 15:50 〜 17:50 Room 14 (G602)

Chair: Masaki Kato (Department of Neuropsychiatry, Kansai Medical University ), Koichiro Watanabe(Department of Neuropsychiatry, Kyorin University School of Medicine)

Co-sponsored by Otsuka Pharmaceutical Co., Ltd. Medical Affairs

+全てマイスケジュールに登録

[CSS6-1] うつ病診療におけるMeasurement based careの考え方：個別化されたリカバリーへのアプローチを精神療法から考える

*菊地俊暁¹ (1. 慶應義塾大学医学部精神・神経科学教室)

[CSS6-2] うつ病労働者復職時の評価について

*堀輝¹ (1. 福岡大学医学部　精神医学教室)

[CSS6-3] 精神科クリニックにおけるIT機器を利用してのMeasurement Based Careの実際について〜ひもろぎ式うつ尺度、不安尺度の活用を通じて〜

*本郷誠司¹ (1. 市ヶ谷ひもろぎクリニック、　南湖こころのクリニック　院長)

Co-sponsored Symposium

Co-sponsored Symposium 7
Toward a disease concept integrating substance dependence and behavioral addiction: Consideration of common background from basic and clinical perspectives

2024年5月25日(土) 15:50 〜 17:50 Room 15 (G610)

Chair: Hisatsugu Miyata (Department of Psychiatry, Jikei University School of Medicine/Hirakawa Hospital), Naoyuki Hironaka (Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science)

Co-sponsored by Smoking Research Foundation

+全てマイスケジュールに登録

[CSS7-1] 行動嗜癖の神経機構解析のためのモデル動物開発

*南雅文¹ (1. 北海道大学大学院薬学研究院薬理学研究室)

[CSS7-2] ドパミン関連遺伝子改変マウスを用いたアディクション解析

*井手聡一郎¹、池田和隆¹ (1. 公益財団法人　東京都医学総合研究所　依存性物質プロジェクト)

[CSS7-3] ニコチン摂取行動に対する嗜癖性の獲得と扁桃体基底外側部の役割

*新田淳美¹ (1. 富山大学学術研究部　薬学・和漢系　薬物治療学研究室)

[CSS7-4] 喫煙行動嗜癖化の要因：喫煙動機、社会的要因の関与

*高田孝二^1,2、高野裕治³、廣中直行⁴ (1. 東京慈恵会医科大学精神医学講座、2. 帝京大学文学部心理学科、3. 人間環境大学総合心理学部総合心理学科、4. 東京都医学総合研究所依存性物質プロジェクト)

[CSS7-5] 物質依存と行動嗜癖を統合した新たな診断基準作成の試み

*宮田久嗣^1,2、山田理沙³、下斗米淳⁴ (1. 東京慈恵会医科大学　精神医学講座、2. 医療法人社団光生会　平川病院、3. 国立研究開発法人国立精神・神経医療研究センター、4. 専修大学人間科学部心理学科)

Co-sponsored Symposium

Co-sponsored Symposium 8
The unmet needs of schizophrenia from various stakeholders' point of view　

2024年5月26日(日) 14:20 〜 15:50 Room 12 (Hall D5)

Chair: Takahiro Nemoto (Department of Neuropsychiatry, Toho University School of Medicine), Satoru Ikezawa( International University of Health and Welfare, IUHW Mita Hospital)

Co-sponsored by Medicine Division, Nippon Boehringer Ingelheim Co., Ltd.

+全てマイスケジュールに登録

[CSS8-1] 統合失調症当事者へのインタビュー（動画）

*山田悠平¹ (1. 一般社団法人精神障害当事者会ポルケ)

[CSS8-2] 統合失調症を抱える当事者のリカバリーに向けた課題～就労支援者の立場から～

*芳賀大輔¹ (1. NPO法人日本学び協会ワンモア豊中・千里中央)

[CSS8-3] 統合失調症当事者のご家族へのインタビュー（動画）

*岡田久実子¹ (1. 公益社団法人全国精神保健福祉会連合会)

[CSS8-4] 統合失調症急性期を乗り越えた後・・・
～精神科医の立場から～

*堀輝¹ (1. 福岡大学　医学部　精神医学教室　教授)

Co-sponsored Symposium

Co-sponsored Symposium 9
The importance of personalizing long-acting injectables and shared decision-making in schizophrenia

2024年5月26日(日) 14:50 〜 15:50 Room 1 (Hall C)

Chair: Norio Furukori (Dokkyo Medical University, Department of Psychiatry)

Co-sponsored by Janssen Asia Pacific

[CSS9] The importance of personalizing long-acting injectables and shared decision-making in schizophrenia management

*John M. Kane¹ (1. The Donald and Barbara Zucker School of Medicine)

セッション一覧

Co-sponsored Symposium / Seminar » Co-sponsored Symposium

Co-sponsored Symposium 1
To Achieve Personal Goals for Patients with Schizophrenia in Patient Centered Care

[CSS1-1] The Significance of Personal Goals in Schizophrenia Treatment: Unmet Needs, Therapeutic Approaches, and Recovery Strategies

[CSS1-2] Optimizing Antipsychotic Treatment for Relapse Prevention and Clinical Recovery in Schizophrenia

[CSS1-3] Psychosocial Treatment with a Focus on Recovery

Co-sponsored Symposium 2
Strategic Approaches to Achieve Recovery

[CSS2-1] MBCによるうつ病診療～症候学的寛解から機能的回復まで～

[CSS2-2] うつ病患者のパーソナルリカバリー達成を目指す上で、いかに治療し、いかに測定するか

Co-sponsored Symposium 3
Cognitive Impairment is a Core Feature of Schizophrenia

[CSS3] Cognitive Impairment Is a Core Feature of Schizophrenia

Co-sponsored Symposium 4
Tobacco Harm Reduction - an Update

[CSS4-1] Harm reduction – origins, successes and untapped potential

[CSS4-2] Smoking, safer nicotine products and tobacco harm reduction―around the world in fifteen minutes

[CSS4-3] Japan tops the world in reducing cigarette sales

[CSS4-4] Can e-cigarettes help tobacco cigarette smokers quit? A review of the evidence

[CSS4-5] Decision-making and habit: understanding maladaptive behaviour from basic animal learning research

Co-sponsored Symposium 5
Which interventions are key to change the trajectory of schizophrenia?

[CSS5] The relevance of nonpsychotic symptoms in the management of schizophrenia

Co-sponsored Symposium 6
Measurement Based Care in depression

[CSS6-1] うつ病診療におけるMeasurement based careの考え方：個別化されたリカバリーへのアプローチを精神療法から考える

[CSS6-2] うつ病労働者復職時の評価について

[CSS6-3] 精神科クリニックにおけるIT機器を利用してのMeasurement Based Careの実際について〜ひもろぎ式うつ尺度、不安尺度の活用を通じて〜

Co-sponsored Symposium 7
Toward a disease concept integrating substance dependence and behavioral addiction: Consideration of common background from basic and clinical perspectives

[CSS7-1] 行動嗜癖の神経機構解析のためのモデル動物開発

[CSS7-2] ドパミン関連遺伝子改変マウスを用いたアディクション解析

[CSS7-3] ニコチン摂取行動に対する嗜癖性の獲得と扁桃体基底外側部の役割

[CSS7-4] 喫煙行動嗜癖化の要因：喫煙動機、社会的要因の関与

[CSS7-5] 物質依存と行動嗜癖を統合した新たな診断基準作成の試み

Co-sponsored Symposium 8
The unmet needs of schizophrenia from various stakeholders' point of view

[CSS8-1] 統合失調症当事者へのインタビュー（動画）

[CSS8-2] 統合失調症を抱える当事者のリカバリーに向けた課題～就労支援者の立場から～

[CSS8-3] 統合失調症当事者のご家族へのインタビュー（動画）

[CSS8-4] 統合失調症急性期を乗り越えた後・・・
～精神科医の立場から～

Co-sponsored Symposium 9
The importance of personalizing long-acting injectables and shared decision-making in schizophrenia

[CSS9] The importance of personalizing long-acting injectables and shared decision-making in schizophrenia management

認証

セッション一覧

Co-sponsored Symposium / Seminar » Co-sponsored Symposium

Co-sponsored Symposium 1To Achieve Personal Goals for Patients with Schizophrenia in Patient Centered Care

Co-sponsored Symposium 2Strategic Approaches to Achieve Recovery

Co-sponsored Symposium 3Cognitive Impairment is a Core Feature of Schizophrenia

Co-sponsored Symposium 4Tobacco Harm Reduction - an Update

Co-sponsored Symposium 5Which interventions are key to change the trajectory of schizophrenia?

Co-sponsored Symposium 6Measurement Based Care in depression

Co-sponsored Symposium 7Toward a disease concept integrating substance dependence and behavioral addiction: Consideration of common background from basic and clinical perspectives

Co-sponsored Symposium 8The unmet needs of schizophrenia from various stakeholders' point of view

Co-sponsored Symposium 9The importance of personalizing long-acting injectables and shared decision-making in schizophrenia

認証

Co-sponsored Symposium 1
To Achieve Personal Goals for Patients with Schizophrenia in Patient Centered Care

Co-sponsored Symposium 2
Strategic Approaches to Achieve Recovery

Co-sponsored Symposium 3
Cognitive Impairment is a Core Feature of Schizophrenia

Co-sponsored Symposium 4
Tobacco Harm Reduction - an Update

Co-sponsored Symposium 5
Which interventions are key to change the trajectory of schizophrenia?

Co-sponsored Symposium 6
Measurement Based Care in depression

Co-sponsored Symposium 7
Toward a disease concept integrating substance dependence and behavioral addiction: Consideration of common background from basic and clinical perspectives

Co-sponsored Symposium 8
The unmet needs of schizophrenia from various stakeholders' point of view　

Co-sponsored Symposium 9
The importance of personalizing long-acting injectables and shared decision-making in schizophrenia